Swedish Orphan Biovitrum reported a 29% increase in revenue at constant exchange rates for the second quarter, with total net sales reaching just under SEK7.8 billion. The company raised its full-year guidance, now expecting revenue growth in the mid- to high teens percentage range at constant exchange rates and an adjusted EBITDA margin in the mid- to high 30s percentage of revenue. Adjusted EBITDA for the quarter came in at SEK2.8 billion, representing a 35% margin, while operating cash flow was SEK1.9 billion and net debt stood just above SEK16 billion, giving a net debt-to-EBITDA ratio of 1.3 times. Growth was driven by strong performances from Doptelet, Altuvoct, and Gamifant, with hemophilia A sales up 41% at constant exchange rates and geographic revenue rising 33% in North America, 45% in international markets, and 23% in Europe. Operating expenses increased 24% at constant exchange rates, including a 15% rise in SG&A and a 47% jump in R&D spending linked to new development programs.
Swedish Orphan Biovitrum ABSwedish Orphan Biovitrum reported 29% revenue growth and raised full-year guidance, with strong product sales and improved margins.
Commercial Metals Company